Buy Like Buffett
Watchlist

Flagship explainer

How NeoGenomics, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$727M · 100%Cost of revenue$413M · 57%Gross profit$314M · 43%Operating income−$116M · −16%Income before tax−$110M · −15%Income tax−$2.2M · −0%Net income−$108M · −15%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$727M100%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
Cost of revenue$413M57%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
$314M43%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
−$116M−16%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
Income before tax−$110M−15%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
Income tax−$2.2M−0%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
−$108M−15%
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001077183-26-000010 · filed Feb 17, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full NeoGenomics, Inc. analysis at Buy Like Buffett